Bevacizumab

Brand Name: Avastin

Manufacturer: Genentech

Indication

Indication:

First-line treatment of metastatic colorectal cancer (mCRC) in patients with metastatic colon or rectal cancer. It is used in combination with fluoropyrimidine-based chemotherapy as part of initial systemic treatment.

Patients may also receive bevacizumab through biosimilars including MVasi (Amgen), Zirabev (Pfizer), and Alymsys (JAMP Pharma).

Specific CRC Subtype: None

Stage: IV

Therapy Line: First-line

Health Canada Approval: Approved

pCPA Negotiation Status:

Reimbursed in: AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), NU (Nunavut), NWT (Northwest Territories), ON (Ontario), PEI (Prince Edward Island), QC (Quebec), SK (Saskatchewan), YU (Yukon)

New Search